ES2315215T1 - Secuencias nucleotidicas del genoma de retrovirus del tipo hiv-1, hiv-2, y siv y sus aplicaciones, en particular para la amplificacion de genomas de estos retrovirus y para el diagnostico in vitro de infecciones debidas a estos virus. - Google Patents
Secuencias nucleotidicas del genoma de retrovirus del tipo hiv-1, hiv-2, y siv y sus aplicaciones, en particular para la amplificacion de genomas de estos retrovirus y para el diagnostico in vitro de infecciones debidas a estos virus. Download PDFInfo
- Publication number
- ES2315215T1 ES2315215T1 ES07025195T ES07025195T ES2315215T1 ES 2315215 T1 ES2315215 T1 ES 2315215T1 ES 07025195 T ES07025195 T ES 07025195T ES 07025195 T ES07025195 T ES 07025195T ES 2315215 T1 ES2315215 T1 ES 2315215T1
- Authority
- ES
- Spain
- Prior art keywords
- hiv
- siv
- sequence
- viruses
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000713772 Human immunodeficiency virus 1 Species 0.000 title claims abstract 25
- 208000031886 HIV Infections Diseases 0.000 title claims 12
- 241000713340 Human immunodeficiency virus 2 Species 0.000 title claims 12
- 241000700605 Viruses Species 0.000 title claims 9
- 230000003321 amplification Effects 0.000 title claims 4
- 238000003199 nucleic acid amplification method Methods 0.000 title claims 4
- 238000003745 diagnosis Methods 0.000 title claims 2
- 238000000338 in vitro Methods 0.000 title claims 2
- 208000015181 infectious disease Diseases 0.000 title claims 2
- 108090000623 proteins and genes Proteins 0.000 title 1
- 241001430294 unidentified retrovirus Species 0.000 title 1
- 108091034117 Oligonucleotide Proteins 0.000 claims abstract 9
- 108700004026 gag Genes Proteins 0.000 claims abstract 5
- 101150098622 gag gene Proteins 0.000 claims abstract 5
- 230000000295 complement effect Effects 0.000 claims abstract 2
- 239000013615 primer Substances 0.000 claims 13
- 150000007523 nucleic acids Chemical class 0.000 claims 8
- 238000000034 method Methods 0.000 claims 6
- 108020004707 nucleic acids Proteins 0.000 claims 6
- 102000039446 nucleic acids Human genes 0.000 claims 6
- 239000012472 biological sample Substances 0.000 claims 4
- 238000004925 denaturation Methods 0.000 claims 4
- 230000036425 denaturation Effects 0.000 claims 4
- 238000009396 hybridization Methods 0.000 claims 4
- 230000015572 biosynthetic process Effects 0.000 claims 3
- 239000002773 nucleotide Substances 0.000 claims 3
- 230000004544 DNA amplification Effects 0.000 claims 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 claims 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 claims 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims 2
- 238000001514 detection method Methods 0.000 claims 2
- 239000011159 matrix material Substances 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 235000011178 triphosphate Nutrition 0.000 claims 2
- 239000001226 triphosphate Substances 0.000 claims 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 claims 1
- 108020004635 Complementary DNA Proteins 0.000 claims 1
- 108020004414 DNA Proteins 0.000 claims 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 claims 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 claims 1
- 108010010803 Gelatin Proteins 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 108010006785 Taq Polymerase Proteins 0.000 claims 1
- 238000010804 cDNA synthesis Methods 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 239000002299 complementary DNA Substances 0.000 claims 1
- 238000000605 extraction Methods 0.000 claims 1
- 229920000159 gelatin Polymers 0.000 claims 1
- 239000008273 gelatin Substances 0.000 claims 1
- 235000019322 gelatine Nutrition 0.000 claims 1
- 235000011852 gelatine desserts Nutrition 0.000 claims 1
- 229910001629 magnesium chloride Inorganic materials 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 239000002777 nucleoside Substances 0.000 claims 1
- -1 nucleotide triphosphates Chemical class 0.000 claims 1
- 238000004321 preservation Methods 0.000 claims 1
- 239000012429 reaction media Substances 0.000 claims 1
- 239000000523 sample Substances 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/702—Specific hybridization probes for retroviruses
- C12Q1/703—Viruses associated with AIDS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
- G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
- G01N2333/16—HIV-1, HIV-2
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/974—Aids related test
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/975—Kit
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- AIDS & HIV (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Tropical Medicine & Parasitology (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Oligonucleótido caracterizado porque su secuencia consiste en: i) una secuencia específica del gen gag, y susceptible de hibridar a una temperatura de 60ºC ñ 1ºC con los genomas de los virus VIH-1 Bru, VIH-1 Mal, VIH-1 Eli, VIH-2 Rod y SIV Mac, o ii) una secuencia complementaria de una secuencia tal como se define en i.
Claims (11)
1. Oligonucleótido caracterizado porque
su secuencia consiste en:
- i)
- una secuencia específica del gen gag, y susceptible de hibridar a una temperatura de 60ºC \pm 1ºC con los genomas de los virus VIH-1 Bru, VIH-1 Mal, VIH-1 Eli, VIH-2 Rod y SIV Mac, o
- ii)
- una secuencia complementaria de una secuencia tal como se define en i.
2. Oligonucleótido según la reivindicación 1,
caracterizado porque tiene un tamaño de aproximadamente 15 a
30 nucleótidos.
3. Oligonucleótido según la reivindicación 1,
caracterizado porque su secuencia nucleotídica tiene al menos
un 60% de identidad con la secuencia del gen gag de los
virus VIH-1 Bru, VIH-1 Mal,
VIH-1 Eli, VIH-2 Rod o SIV Mac y
mantiene las propiedades de hibridación con los genomas de los virus
VIH-1 Bru, VIH-1 Mal,
VIH-1 Eli, VIH-2 Rod y SIV Mac.
4. Oligonucleótido que comprende una
conservación de al menos 5 bases de cada lado del cebador con
respecto a la secuencia de un cebador oligonucleotídico tal como se
describe en las reivindicaciones 1 a 3, y que comprende en su parte
media modificaciones con respecto a la secuencia de un cebador
oligonucleotídico según las reivindicaciones 1 a 3 y mantiene las
propiedades de hibridación con los genomas de los virus
VIH-1 Bru, VIH-1 Mal,
VIH-1 Eli, VIH-2 Rod y SIV Mac.
5. Oligonucleótido según una cualquiera de las
reivindicaciones 1 a 4, susceptible de hibridar con los genomas de
los virus VIH-1 Bru, VIH-1 Mal,
VIH-1 Eli, VIH-2 Rod y SIV Mac en un
tampón de composición Tris-HCl, pH 8,9: 50 mM;
(NH_{4})_{2}SO_{4}: 15 mM; MgCl_{2}: 5 mM;
\beta-mercaptoetanol: 10 mM; gelatina: 0,25
mg/ml.
6. Procedimiento de amplificación génica de
secuencias nucleicas del gen gag de virus del tipo
VIH-1 y/o VIH-2 y/o SIV, realizado
a partir de una muestra biológica, comprendiendo este procedimiento
principalmente las etapas siguientes:
- a)
- una etapa de extracción del ácido nucleico para detectar que pertenece al genoma del virus de tipo VIH-1, VIH-2 o SIV eventualmente presente en la muestra biológica anteriormente mencionada y, en su caso, una etapa de tratamiento con la ayuda de una transcriptasa inversa de dicho ácido nucleico si este último está en forma de ARN,
- b)
- un ciclo que comprende las etapas siguientes:
- -
-
\vtcortauna
- -
-
\vtcortauna
- -
-
\vtcortauna
- \quad
- repitiéndose este ciclo un número de veces determinado para obtener dicha secuencia nucleica a detectar eventualmente presente en la muestra biológica en una proporción suficiente para permitir su detección;
- c)
- una etapa de detección de la presencia eventual del ácido nucleico que pertenece al genoma de virus de tipo VIH-1 y/o VIH-2 y/o SIV en la muestra biológica.
7. Procedimiento según la reivindicación 6,
caracterizado porque la etapa de desnaturalización se realiza
en presencia de al menos un cebador según una de las
reivindicaciones 1 a 5.
8. Procedimiento según la reivindicación 7,
caracterizado porque se realiza en las condiciones
siguientes:
- a)
- hibridación: los cebadores (1 \mul de una solución 40 \muM de cada cebador) se ponen en presencia del ADN-matriz (100 a 300 ng) para la primera etapa de desnaturalización-reasociación; se calienta durante 10 minutos a 100ºC, después se sumergen los tubos que contienen esta mezcla de ADN-matriz y cebadores en agua que contiene hielo. Los cebadores deben utilizarse a una concentración final en la etapa de amplificación siguiente de 0,8 \muM cada uno,
- b)
- amplificación: se añaden al medio precedente los 4 dNTP, utilizado cada uno a 0,5 \muM en la solución final (50 \mul), y una unidad de polimerasa Taq para un medio de reacción de 50 \mul.
9. Aplicación del procedimiento según una
cualquiera de las reivindicaciones 6 a 8 al diagnóstico in
vitro de infección en un individuo por un virus del tipo
VIH-1 y/o VIH-2, o en un animal por
al menos uno de los tres virus (VIH-1,
VIH-2, SIV).
10. Kit para la puesta en práctica de un
procedimiento según una de las reivindicaciones 6 a 8 que
comprende:
- i)
- al menos un cebador oligonucleotídico según una cualquiera de las reivindicaciones 1 a 5,
- ii)
- reactivos apropiados para la puesta en práctica del ciclo de operaciones de amplificación, particularmente ADN polimerasa, cuatro trifosfatos de nucleótido diferentes y el tampón 10 x tal como se describe en la reivindicación 5,
- iii)
- una (o más) sonda que puede estar marcada, capaz de hibridar con la (o las) secuencia(s) de ácido nucleico amplificada(s) a detectar.
11. Utilización de al menos un cebador según una
cualquiera de las reivindicaciones 1 a 5 para la amplificación
génica de secuencias nucleicas del gen gag de virus de tipo
VIH-1 y/o VIH-2 y/o SIV.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR8907354 | 1989-06-02 | ||
FR8907354A FR2647809B1 (fr) | 1989-06-02 | 1989-06-02 | Amorces oligonucleotidiques pour l'amplification du genome des retrovirus du type hiv-1, hiv-2 et siv, et leurs applications au diagnostic in vitro des infections dues a ces virus |
FR8912371 | 1989-09-20 | ||
FR8912371A FR2652091B1 (fr) | 1989-09-20 | 1989-09-20 | Sequences nucleotidiques issues du genome des retrovirus du type hiv-1, hiv-2 et siv, et leurs applications notamment pour l'amplification des genomes de ces retrovirus et pour le diagnostic in-vitro des infections dues a ces virus. |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2315215T1 true ES2315215T1 (es) | 2009-04-01 |
Family
ID=26227366
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES97110543T Expired - Lifetime ES2262166T3 (es) | 1989-06-02 | 1990-06-05 | Sintesis de proteinas o polipeptidos codificados por un secuencia nucleotidica vih-1, vih-2 o siv. |
ES06013029T Expired - Lifetime ES2321326T3 (es) | 1989-06-02 | 1990-06-05 | Secuencias nucleotidicas procedentes del genoma de los retrovirus del tipo vih-1, vih-2 y vis, y sus aplicaciones especialmente para la amplificacion de secuencias del pol de estos genomas de estos retrovirus y para el diagnostico invitro de las infecciones debidas a estos virus. |
ES05014676T Expired - Lifetime ES2275451T3 (es) | 1989-06-02 | 1990-06-05 | Secuencias nucleotidicas procedentes del genoma de los retrovirus del tipo vih-1,vih-2 y siv, y sus aplicaciones especialmente para la amplificacion de los genomas de estos retrovirus y para el diagnostico in vitro de las infecciones debidas a estos virus. |
ES07025195T Pending ES2315215T1 (es) | 1989-06-02 | 1990-06-05 | Secuencias nucleotidicas del genoma de retrovirus del tipo hiv-1, hiv-2, y siv y sus aplicaciones, en particular para la amplificacion de genomas de estos retrovirus y para el diagnostico in vitro de infecciones debidas a estos virus. |
ES90401520T Expired - Lifetime ES2139567T3 (es) | 1989-06-02 | 1990-06-05 | Secuencias nucleotidicas procedentes del genoma de retrovirus del tipo vih-1 y sus aplicaciones para la amplificacion de los genomas de estos retrovirus y para el diagnostico in vitro de las infecciones producidas por estos virus. |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES97110543T Expired - Lifetime ES2262166T3 (es) | 1989-06-02 | 1990-06-05 | Sintesis de proteinas o polipeptidos codificados por un secuencia nucleotidica vih-1, vih-2 o siv. |
ES06013029T Expired - Lifetime ES2321326T3 (es) | 1989-06-02 | 1990-06-05 | Secuencias nucleotidicas procedentes del genoma de los retrovirus del tipo vih-1, vih-2 y vis, y sus aplicaciones especialmente para la amplificacion de secuencias del pol de estos genomas de estos retrovirus y para el diagnostico invitro de las infecciones debidas a estos virus. |
ES05014676T Expired - Lifetime ES2275451T3 (es) | 1989-06-02 | 1990-06-05 | Secuencias nucleotidicas procedentes del genoma de los retrovirus del tipo vih-1,vih-2 y siv, y sus aplicaciones especialmente para la amplificacion de los genomas de estos retrovirus y para el diagnostico in vitro de las infecciones debidas a estos virus. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES90401520T Expired - Lifetime ES2139567T3 (es) | 1989-06-02 | 1990-06-05 | Secuencias nucleotidicas procedentes del genoma de retrovirus del tipo vih-1 y sus aplicaciones para la amplificacion de los genomas de estos retrovirus y para el diagnostico in vitro de las infecciones producidas por estos virus. |
Country Status (12)
Country | Link |
---|---|
US (6) | US5688637A (es) |
EP (5) | EP0806484B1 (es) |
JP (2) | JP3428012B2 (es) |
AT (5) | ATE404699T1 (es) |
CA (3) | CA2062829C (es) |
DE (7) | DE07025195T1 (es) |
DK (5) | DK2011888T3 (es) |
ES (5) | ES2262166T3 (es) |
GR (1) | GR3032261T3 (es) |
HK (3) | HK1125136A1 (es) |
SG (1) | SG47868A1 (es) |
WO (1) | WO1990015066A2 (es) |
Families Citing this family (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0806484B1 (fr) * | 1989-06-02 | 2006-04-12 | Institut Pasteur | Synthèse de protéines ou de polypeptides codés par une séquence nucléotidique de HIV-1, HIV-2 ou SIV. |
US7022814B1 (en) | 1992-01-21 | 2006-04-04 | Institut Pasteur And Institut National De La Sante Et De La Recherche Medicale | Nucleotide sequences derived from the genome of retroviruses of the HIV-1, HIV-2 and SIV type, and their uses in particular for the amplification of the genomes of these retroviruses and for the in vitro diagnosis of the diseases due to these viruses |
US5856088A (en) * | 1989-07-11 | 1999-01-05 | Gen-Probe Incorporated | Detection of human immunodeficiency virus type 1 |
US6589734B1 (en) | 1989-07-11 | 2003-07-08 | Gen-Probe Incorporated | Detection of HIV |
JPH04152899A (ja) * | 1990-10-17 | 1992-05-26 | Shionogi & Co Ltd | 2段階pcr法によるhiv―1ゲノムの検出法およびオリゴヌクレオチド |
FR2677039B1 (fr) * | 1991-05-31 | 1994-09-09 | Cis Bio Int | Oligonucleotides, utilisables comme reactifs pour la detection in vitro des infections a retrovirus de type hiv et procede de detection de retrovirus de type hiv. |
CA2124797C (en) * | 1991-12-23 | 2004-03-30 | Bruce D. Irvine | Hiv probes for use in solution phase sandwich hybridization assays |
FR2692279B1 (fr) * | 1992-06-16 | 1995-05-19 | Centre Nat Rech Scient | Séquences nucléotidiques issues de la souche WO du vif et leurs fragments, applications desdites séquences à l'expression de peptides immunogènes et au diagnostic de l'immunodéficience féline. |
WO1994023069A1 (en) | 1993-03-26 | 1994-10-13 | Gen-Probe Incorporated | Detection of human immunodeficiency virus type 1 |
AU7568794A (en) * | 1993-08-20 | 1995-03-21 | St. Luke's-Roosevelt Hospital Center | Hiv (vif)-related compositions, and prophylactic and therapeutic uses thereof |
US5733781A (en) * | 1994-07-19 | 1998-03-31 | Gen-Probe Incorporated | Oligonucleotides and methods for inhibiting propagation of human immunodeficiency virus |
JP2000501931A (ja) | 1995-12-05 | 2000-02-22 | ドナルド アール. ブランチ | Hiv感染を早期に検出する方法 |
US6265152B1 (en) * | 1995-12-22 | 2001-07-24 | Visible Genetics Inc. | Method and kit for evaluation of HIV mutations |
DE19644248A1 (de) * | 1996-10-24 | 1998-04-30 | Boehringer Mannheim Gmbh | Primer und Probes zum Nachweis von HIV |
US6830887B2 (en) | 1997-03-18 | 2004-12-14 | Bayer Healthcare Llc | Method and kit for quantitation and nucleic acid sequencing of nucleic acid analytes in a sample |
US5962665A (en) * | 1997-06-16 | 1999-10-05 | Abbott Laboratories | Nucleic acid primers and probes for detecting HIV-1 and HIV-2 |
US6001558A (en) * | 1997-06-25 | 1999-12-14 | Ortho Clinical Diagnostics, Inc. | Amplification and detection of HIV-1 and/or HIV 2 |
US6228128B1 (en) | 1997-11-10 | 2001-05-08 | Charlotte Johansen | Antimicrobial activity of laccases |
DE19850186A1 (de) * | 1998-10-30 | 2000-05-25 | Roche Diagnostics Gmbh | Neue Primer und Sonden zum Nachweis von HIV |
US6303293B1 (en) * | 1999-02-02 | 2001-10-16 | Ortho-Clinical Diagnostics, Inc. | Oligonucleotide reverse transcription primers for efficient detection of HIV-1 and HIV-2 and methods of use thereof |
AU3219400A (en) * | 1999-02-03 | 2000-08-25 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Methods and reagents for molecular detection of hiv-1 groups m, n and |
DE19908766C2 (de) * | 1999-02-19 | 2001-02-15 | Ulrich Schubert | Verwendung synthetischer Vpr-Peptide des Humanen Immundefizienzvirus Typ 1 (HIV-1) zur Entwicklung von therapeutischen und diagnostischen Reagenzien |
AU3438999A (en) * | 1999-05-07 | 2000-11-21 | Nationales Zentrum Fur Retroviren | Detection system for human immunodeficiency virus based on nucleic acid amplification |
FR2798385B1 (fr) * | 1999-06-21 | 2003-09-05 | Bio Merieux | Procede de recherche d'une resistance aux anti-proteases chez des souches du virus vih-2 |
ATE456677T1 (de) | 1999-07-09 | 2010-02-15 | Gen Probe Inc | Hiv-1 detektion mittels nukleinsäureamplifizierung |
US20030228600A1 (en) * | 2000-07-14 | 2003-12-11 | Eppendorf 5 Prime, Inc. | DNA isolation method and kit |
CA2731495C (en) | 2000-09-01 | 2015-02-03 | Gen-Probe Incorporated | Amplification of hiv-1 sequences for detection of sequences associated with drug-resistance mutations |
US6582920B2 (en) | 2000-09-01 | 2003-06-24 | Gen-Probe Incorporated | Amplification of HIV-1 RT sequences for detection of sequences associated with drug-resistance mutations |
AU3054502A (en) | 2000-10-23 | 2002-05-06 | Gen Probe Inc | Compositions and methods for detecting human immunodeficiency virus 2 (hiv-2) |
US6770752B2 (en) | 2001-01-09 | 2004-08-03 | Becton, Dickinson And Company | Sequences for detection of HIV-1 |
WO2002070731A2 (en) * | 2001-03-05 | 2002-09-12 | Visible Genetics Inc. | Methods and primers for evaluating hiv-1 mutations |
JP4701532B2 (ja) * | 2001-04-26 | 2011-06-15 | 東ソー株式会社 | Hiv−1rnaの増幅および検出法 |
CN1620309A (zh) * | 2001-12-18 | 2005-05-25 | 蒙多生物技术实验室 | 用于结合分子诊断法改进间质性肺疾病的治疗的干扰素γ或甲苯吡啶酮的新型药物组合物 |
US20030215793A1 (en) * | 2002-01-17 | 2003-11-20 | Hahn Beatrice H. | Complete genome sequence of a simian immunodeficiency virus from a wild chimpanzee |
CN1301263C (zh) | 2002-12-18 | 2007-02-21 | 北京昭衍新药研究中心 | 一组抗hiv感染及防治艾滋病的核苷酸序列及其应用 |
US20050222068A1 (en) | 2003-10-23 | 2005-10-06 | Mourich Dan V | Method and antisense composition for selective inhibition of HIV infection in hematopoietic cells |
CA2547750C (en) | 2003-12-19 | 2014-04-08 | Gen-Probe Incorporated | Compositions, methods and kits for detecting the nucleic acids of hiv-1 and hiv-2 |
TW200613554A (en) | 2004-06-17 | 2006-05-01 | Wyeth Corp | Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV |
EP1765867B1 (en) | 2004-07-01 | 2015-12-09 | The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services | Monoclonal antibodies to hiv-1 vpr and methods of using same |
PL1794327T3 (pl) | 2004-09-14 | 2017-04-28 | Argos Therapeutics, Inc. | Niezależna od szczepu amplifikacja patogenów i szczepionki przeciwko nim |
US20090050492A1 (en) * | 2005-08-02 | 2009-02-26 | Board Of Trustees Of Michigan State University | Nanoporous silicon-based electrochemical nucleic acid biosensor |
CN101680027A (zh) * | 2007-03-16 | 2010-03-24 | 454生命科学公司 | 检测hiv耐药变异体的系统和方法 |
US8221981B2 (en) * | 2007-07-30 | 2012-07-17 | Argos Therapeutics, Inc. | Primers and probes for the amplification and detection of HIV Gag, Rev and Nef polynucleotides |
US8405379B1 (en) | 2008-09-18 | 2013-03-26 | Luc Montagnier | System and method for the analysis of DNA sequences in biological fluids |
US10545149B2 (en) * | 2008-10-06 | 2020-01-28 | Morehouse School Of Medicine | Detection of HIV-related proteins in urine |
WO2010080554A1 (en) | 2008-12-17 | 2010-07-15 | Avi Biopharma, Inc. | Antisense compositions and methods for modulating contact hypersensitivity or contact dermatitis |
ES2625406T3 (es) | 2010-03-25 | 2017-07-19 | Oregon Health & Science University | Glicoproteínas de CMV y vectores recombinantes |
ES2667425T3 (es) | 2011-06-10 | 2018-05-10 | Oregon Health & Science University | Glucoproteínas y vectores recombinantes de CMV |
CN102964898B (zh) | 2011-08-05 | 2016-05-25 | 罗门哈斯公司 | 具有改进的亲水污渍排斥性的水性涂料组合物 |
EP2568289A3 (en) | 2011-09-12 | 2013-04-03 | International AIDS Vaccine Initiative | Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies |
EP2586461A1 (en) | 2011-10-27 | 2013-05-01 | Christopher L. Parks | Viral particles derived from an enveloped virus |
ES2631608T3 (es) | 2012-06-27 | 2017-09-01 | International Aids Vaccine Initiative | Variante de la glicoproteína Env del VIH-1 |
EP2848937A1 (en) | 2013-09-05 | 2015-03-18 | International Aids Vaccine Initiative | Methods of identifying novel HIV-1 immunogens |
EP2873423B1 (en) | 2013-10-07 | 2017-05-31 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
EP3069730A3 (en) | 2015-03-20 | 2017-03-15 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
US9931394B2 (en) | 2015-03-23 | 2018-04-03 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3587181T2 (de) * | 1984-10-18 | 1993-06-24 | Centre Nat Rech Scient | F antigene vom menschlichen immunodefizienz-virus und deren verwendungen. |
US5386022A (en) | 1985-03-28 | 1995-01-31 | Hoffman-La Roche Inc. | Primes and probes for the amplification and detection of aids associated nucleic acids |
AU606043B2 (en) | 1985-03-28 | 1991-01-31 | F. Hoffmann-La Roche Ag | Detection of viruses by amplification and hybridization |
US5176995A (en) | 1985-03-28 | 1993-01-05 | Hoffmann-La Roche Inc. | Detection of viruses by amplification and hybridization |
ES8706823A1 (es) | 1985-03-28 | 1987-06-16 | Cetus Corp | Un procedimiento para detectar la presencia o ausencia de al menos una secuencia especifica de acidos nucleicos en una muestra |
US5008182A (en) | 1986-01-10 | 1991-04-16 | Cetus Corporation | Detection of AIDS associated virus by polymerase chain reaction |
US4683195A (en) * | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US5008185A (en) | 1985-11-04 | 1991-04-16 | Cell Analysis Systems, Inc. | Methods and apparatus for the quantitation of nuclear proteins |
US4839288A (en) * | 1986-01-22 | 1989-06-13 | Institut Pasteur | Retrovirus capable of causing AIDS, antigens obtained from this retrovirus and corresponding antibodies and their application for diagnostic purposes |
NZ219024A (en) | 1986-01-22 | 1990-04-26 | Pasteur Institut | Hiv-2 retrovirus protein and nucleic acid sequences and detection methods |
US4806463A (en) * | 1986-05-23 | 1989-02-21 | Worcester Foundation For Experimental Biology | Inhibition of HTLV-III by exogenous oligonucleotides |
US5824482A (en) * | 1986-06-23 | 1998-10-20 | Institut Pasteur | Purification, cloning, and characterization of a novel human immunodeficiency virus LAVMAL |
US5030714A (en) * | 1986-06-23 | 1991-07-09 | Institut Pasteur | Variant of LAV viruses |
WO1988001302A1 (en) * | 1986-08-11 | 1988-02-25 | Siska Diagnostics, Inc. | Nucleic acid probe assay methods and compositions |
EP0269520A3 (fr) * | 1986-11-21 | 1988-08-24 | Institut Pasteur | Rétrovirus du type HIV-2 susceptible de provoquer le sida, et ses constituants antigéniques et nucléiques |
US5268268A (en) | 1986-11-26 | 1993-12-07 | Hoffmann-La Roche Inc. | Detection of HTLVI and HTLVII viruses by hybridization |
US5079351A (en) | 1986-11-26 | 1992-01-07 | Cetus Corporation | Oligonucleotides and kits for detection of htlvi and htlvii viruses by hybridization |
EP0272098A3 (en) * | 1986-12-15 | 1990-06-06 | City Of Hope National Medical Center | Method for amplification and detection of rna sequences |
ATE154808T1 (de) * | 1987-01-16 | 1997-07-15 | Pasteur Institut | Peptide mit den immunologischen eigenschaften von hiv-2 |
WO1989001050A1 (en) | 1987-07-31 | 1989-02-09 | The Board Of Trustees Of The Leland Stanford Junior University | Selective amplification of target polynucleotide sequences |
US4963532A (en) | 1987-11-25 | 1990-10-16 | Hem Research, Inc. | dsRNA-based prevention of viral escape |
US5389512A (en) | 1988-10-07 | 1995-02-14 | Hoffman-La Roche Inc. | Method for determining the relative amount of a viral nucleic acid segment in a sample by the polymerase chain reaction |
FR2647856B1 (fr) * | 1989-05-31 | 1994-03-04 | Framatome | Dispositif auxiliaire de relachement commande a distance pour un mecanisme a action positive |
EP0806484B1 (fr) * | 1989-06-02 | 2006-04-12 | Institut Pasteur | Synthèse de protéines ou de polypeptides codés par une séquence nucléotidique de HIV-1, HIV-2 ou SIV. |
-
1990
- 1990-06-05 EP EP97110543A patent/EP0806484B1/fr not_active Expired - Lifetime
- 1990-06-05 ES ES97110543T patent/ES2262166T3/es not_active Expired - Lifetime
- 1990-06-05 ES ES06013029T patent/ES2321326T3/es not_active Expired - Lifetime
- 1990-06-05 EP EP90401520A patent/EP0403333B1/fr not_active Expired - Lifetime
- 1990-06-05 DK DK07025195.4T patent/DK2011888T3/da active
- 1990-06-05 DE DE07025195T patent/DE07025195T1/de active Pending
- 1990-06-05 DK DK90401520T patent/DK0403333T3/da active
- 1990-06-05 ES ES05014676T patent/ES2275451T3/es not_active Expired - Lifetime
- 1990-06-05 DK DK06013029T patent/DK1715064T3/da active
- 1990-06-05 DK DK97110543T patent/DK0806484T3/da active
- 1990-06-05 DE DE69033311T patent/DE69033311T2/de not_active Expired - Lifetime
- 1990-06-05 CA CA002062829A patent/CA2062829C/fr not_active Expired - Lifetime
- 1990-06-05 DE DE69034265T patent/DE69034265D1/de not_active Expired - Lifetime
- 1990-06-05 AT AT05014676T patent/ATE404699T1/de not_active IP Right Cessation
- 1990-06-05 DK DK05014676T patent/DK1642987T3/da active
- 1990-06-05 EP EP07025195A patent/EP2011888B1/fr not_active Expired - Lifetime
- 1990-06-05 WO PCT/FR1990/000393 patent/WO1990015066A2/fr active Application Filing
- 1990-06-05 DE DE69034260T patent/DE69034260D1/de not_active Expired - Lifetime
- 1990-06-05 AT AT97110543T patent/ATE323183T1/de not_active IP Right Cessation
- 1990-06-05 AT AT07025195T patent/ATE466111T1/de not_active IP Right Cessation
- 1990-06-05 ES ES07025195T patent/ES2315215T1/es active Pending
- 1990-06-05 EP EP05014676A patent/EP1642987B1/fr not_active Expired - Lifetime
- 1990-06-05 JP JP50891190A patent/JP3428012B2/ja not_active Expired - Lifetime
- 1990-06-05 EP EP06013029A patent/EP1715064B1/fr not_active Expired - Lifetime
- 1990-06-05 DE DE69034267T patent/DE69034267D1/de not_active Expired - Lifetime
- 1990-06-05 SG SG1996004845A patent/SG47868A1/en unknown
- 1990-06-05 DE DE69034220T patent/DE69034220T2/de not_active Expired - Lifetime
- 1990-06-05 CA CA002685262A patent/CA2685262A1/fr not_active Abandoned
- 1990-06-05 DE DE05014676T patent/DE05014676T1/de active Pending
- 1990-06-05 AT AT06013029T patent/ATE423856T1/de not_active IP Right Cessation
- 1990-06-05 CA CA002585164A patent/CA2585164C/fr not_active Expired - Lifetime
- 1990-06-05 AT AT90401520T patent/ATE185379T1/de not_active IP Right Cessation
- 1990-06-05 ES ES90401520T patent/ES2139567T3/es not_active Expired - Lifetime
-
1993
- 1993-12-02 US US08/160,465 patent/US5688637A/en not_active Expired - Fee Related
-
1995
- 1995-06-07 US US08/472,928 patent/US7078516B1/en not_active Expired - Lifetime
-
1997
- 1997-07-16 US US08/895,231 patent/US5786177A/en not_active Expired - Lifetime
-
1998
- 1998-06-05 US US09/092,077 patent/US6194142B1/en not_active Expired - Lifetime
-
1999
- 1999-09-24 JP JP11270165A patent/JP2000093187A/ja active Pending
- 1999-12-28 GR GR990403346T patent/GR3032261T3/el unknown
-
2004
- 2004-06-08 US US10/862,363 patent/US7759477B2/en not_active Expired - Lifetime
-
2005
- 2005-08-15 US US11/203,127 patent/US7777020B2/en not_active Expired - Lifetime
-
2006
- 2006-09-21 HK HK09100744.0A patent/HK1125136A1/xx unknown
- 2006-09-21 HK HK06110565.8A patent/HK1092839A1/xx not_active IP Right Cessation
- 2006-09-21 HK HK07103317.3A patent/HK1097574A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2315215T1 (es) | Secuencias nucleotidicas del genoma de retrovirus del tipo hiv-1, hiv-2, y siv y sus aplicaciones, en particular para la amplificacion de genomas de estos retrovirus y para el diagnostico in vitro de infecciones debidas a estos virus. | |
ES2961374T3 (es) | Amplificación con cebadores de composición de nucleótidos limitada | |
ES2254505T3 (es) | Metodo para la amplificacion y caracterizacion opcional de acidos nucleicos. | |
US5389512A (en) | Method for determining the relative amount of a viral nucleic acid segment in a sample by the polymerase chain reaction | |
ES2703792T3 (es) | Detección de ácidos nucleicos mediante amplificación basada en invasión de hebra | |
ES2759339T3 (es) | Conversión de secuencia y ADN amplificador de señal que tiene ácidos nucleicos bloqueados y métodos de detección que usan los mismos | |
JP6876437B2 (ja) | 鎖侵入に基づくdna増幅法 | |
EP2225393A1 (en) | Method for hybridizing nucleic acids | |
CN104350159B (zh) | 制备在利用核酸聚合酶来检测核酸时使用的高精度核酸的方法 | |
ES2268809T3 (es) | Un metodo de amplificacion basada en la transcripcion de dianas de adn de doble hebra. | |
ES2685710T3 (es) | Kits que comprenden controles para amplificación de ácido nucleico | |
ES2336807T3 (es) | Deteccion del tipo y subtipo del vih. | |
ES2622908T3 (es) | Ensayo de Neisseria gonorrhoeae | |
CN116348614A (zh) | 开关寡核苷酸 | |
US9074248B1 (en) | Primers for helicase dependent amplification and their methods of use | |
ES2362987T3 (es) | Nuevo oligonucleótido marcado. | |
EP4198143A1 (en) | Modified primers for loop-mediated isothermal amplification and use thereof | |
JP2020202766A (ja) | プライマー及びWT1 mRNAの検出方法 | |
KR20240023114A (ko) | Lida(lesion induced dna amplification)에 의한 sars-cov-2 분석 | |
WO2023156837A9 (es) | Composiciones y métodos para detectar sars-cov-2 en muestras clínicas humanas | |
CA2215349A1 (en) | Method of detecting gene expression and/or of preventing such expression in cells |